natgillin/translations-raw huggingface dataset:
Nine out of 56 patients were persistently positive (anti-vedolizumab antibody-positive at two or more study visits) and 33 patients developed neutralizing anti-vedolizumab antibodies.
Persistentno pozitivnih (pozitivnih na protitelesa proti vedolizumabu pri dveh ali več študijskih obiskih) je bilo 9 od 56 bolnikov, nevtralizacijska protitelesa proti vedolizumabu pa so se razvila pri 33 bolnikih.
Nine patients treated with ofatumumab and chlorambucil, and three patients treated with chlorambucil alone had late onset neutropenia, defined as Grade 3 or 4 neutropenia starting at least 42 days after the last treatment.
Devet bolnikov, zdravljenih z ofatumumabom in klorambucilom, in trije bolniki, zdravljeni samo s klorambucilom, so imeli nevtropenijo s poznim nastankom, ki je opredeljena kot nevtropenija 3. ali 4. stopnje in se ne pojavi prej kot 42 dni po zadnjem zdravljenju.
Nine pre-specified adverse event categories were evaluated (cardiovascular thromboembolic events, pericarditis, new onset or exacerbation of congestive heart failure, renal failure/dysfunction, upper GI ulcer complications, major non-GI bleeds, infections, non-infectious pulmonary complications, and death).
Ocenjevali so devet vnaprej določenih kategorij neželenih dogodkov (kardiovaskularni/trombembolični dogodki, perikarditis, ponovni pojav ali poslabšanje kongestivnega srčnega popuščanja, odpoved/slabo delovanje ledvic, zapleti z razjedami v zgornjih prebavilih, močne krvavitve, ki ne izvirajo iz prebavil, infekcije, neinfektivni pulmonalni zapleti in smrt).
Nine treatment cycles of this combination therapy are administered.
Zdravljenje z zdravilom Bortezomib Hospira traja devet krogov.
Nine years after vaccination, 94%, 96%, 99% and 60% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 98%, 96%, 100% and 91% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.
Devet let po cepljenju je bilo 94 %, 96 %, 99 % oziroma 60 % oseb seropozitivnih po metodi cLIA za anti-HPV 6, anti-HPV 11, anti-HPV 16 oziroma anti-HPV 18, ter 98 %, 96 %, 100 % oziroma 91 % oseb seropozitivnih po metodi IgG LIA za anti-HPV 6, anti-HPV 11, anti-HPV 16 oziroma anti-HPV 18.
Nine- day-old broilers from the group of chicks vaccinated at one-day-old were challenged with MD virus and 82% of the chickens were protected compared with 12% in the unvaccinated group.
Devet dni stare pitovne piščance iz skupine cepljenih, en dan starih piščancev so v laboratoriju izpostavili virusu Marekove bolezni in ugotovili, da je bilo zaščitenih 82 % cepljenih piščancev, v necepljeni skupini pa 12 %.
Nine-day- old broilers from the chicks vaccinated at one-day-old were challenged with MD virus and Vectormune ND provided protection to 90% of the chickens compared with 9-12% in the unvaccinated group.
Devet dni stare pitovne piščance iz skupine cepljenih, en dan starih piščancev so v laboratoriju izpostavili virusu Marekove bolezni, pri čemer je cepivo Vectormune ND omogočilo 90-odstotno zaščito, medtem ko je bila zaščita v necepljeni skupini od 9- do 12-odstotna.
Nineteen (19) of the cases of localised pallor were not associated with any other adverse events; only 5 out of these 19 patients discontinued treatment as a result of the pallor.
Devetnajst (19) primerov lokalizirane bledice ni bilo povezanih z nobenim drugim neželenim dogodkom; le 5 od teh 19 bolnikov je zaradi bledice prekinilo zdravljenje.
Ninety nine patients were treated with MabThera and 12% experienced at least one IRR.
Z zdravilom MabThera se je zdravilo 99 bolnikov in pri 12 % bolnikov se je pojavila vsaj ena IRR.
Ninety patients randomised to placebo + BR crossed over to receive IMBRUVICA following IRC confirmed progression.
Ko je IRC potrdila napredovanje bolezni, je 90 bolnikov, ki so bili randomizirani na placebo + BR prešlo na zdravljenje z zdravilom IMBRUVICA.
Ninety-eight (98) of the original 110 patients continued treatment in a second supportive study and had subsequent extended exposure to ReFacto AF with a median of 169 additional ED (range 9-425).
Osemindevetdeset (98) od začetnih 110 bolnikov je nadaljevalo zdravljenje v drugi podporni študiji in je imelo poznejšo podaljšano izpostavljenost zdravilu ReFacto AF z mediano 169 dodatnih ED (razpon 9-425).
Ninety-eight percent (98 %) of subjects received prior doxorubicin, 70 % prior ifosfamide, and 65 % of subjects had received at least three or more chemotherapeutic agents prior to study enrolment.
Osemindevetdeset odstotkov (98 %) preiskovancev je predhodno prejemalo doksorubicin, 70 % ifosfamid in 65 % preiskovancev je pred vključitvijo v študijo prejelo vsaj tri ali več kemoterapevtskih sredstev.
Ninety-eight percent of all subjects receiving palivizumab completed the study and 97% received all five injections.
Osemindevetdeset odstotkov vseh oseb, ki so prejemale palivizumab, je študijo zaključilo in 97 % je prejelo vseh 5 injekcij.
Ninety-five percent of nucleos(t)ide-naïve patients, 84% of nucleos(t)ide- experienced patients, and 83% of lamivudine-resistant patients achieved HBV DNA < 400 copies/ml at week 72.
Petindevetdeset odstotkov bolnikov, ki se predhodno še niso zdravili z nukleoz(t)idi, 84% bolnikov, ki so se predhodno že zdravili z z nukleoz(t)idi in 83% bolnikov, rezistentnih na lamivudin, je doseglo koncentracijo HBV DNA < 400 kopij/ml v 72. tednu.
Ninety-five percent of the patients received their infusion two or more weeks after the hip fracture repair and the median timing of infusion was approximately six weeks after the hip fracture repair.
Petindevetdeset odstotkov bolnikov je prejelo infuzijo dva ali več tednov po oskrbi zloma kolka, pri tem je bil mediani čas odmerjanja infuzije približno šest tednov po oskrbi zloma kolka.
Ninety-seven patients were enrolled at various doses and schedules; 55 patients received 50 mg at the recommended treatment schedule 4 weeks on /2 weeks off (“schedule 4/2”).
Vključenih je bilo 97 bolnikov z različnimi odmerki in shemami; 55 bolnikov je prejemalo 50 mg po priporočeni terapevtski shemi 4 tedne da / 2 tedna ne (''shema 4/2'').
Ninety-seven percent of patients (37 out of 39 patients treated with teduglutide) that completed the placebo-controlled study entered a long-term extension study where all patients received 0.05 mg/kg of Revestive daily for up to an additional 2 years.
Sedemindevetdeset odstotkov bolnikov (37 od 39 bolnikov, zdravljenih s teduglutidom), ki so zaključili s placebom kontrolirano študijo, je vstopilo v dolgoročno podaljšano študijo, v kateri so vsi bolniki prejemali 0,05 mg/kg zdravila Revestive dnevno do 2 dodatni leti.
Ninety-seven percent of the patients who completed the randomised trials in patients with partial onset seizures were enrolled in the open label extension study (n=1186).
Sedemindevetdeset odstotkov bolnikov, ki so končali randomizirano preskušanje pri bolnikih z napadi parcialnega izvora, je bilo vključenih v podaljšek odprte študije (n = 1.186).
Ninety-six percent of patients on dabrafenib monotherapy in the integrated safety population and all patients on combination therapy in the Phase III studies who developed cuSCC continued on treatment without dose modification.
Šestindevetdeset odstotkov bolnikov z monoterapijo z dabrafenibom v skupni varnostni populaciji in vsi bolniki s kombiniranim zdravljenjem v študijah faze III, ki se jim je pojavil ploščatocelični karcinom kože, so nadaljevali zdravljenje brez prilagoditve odmerka.
Ninety-three of these patients had advanced disease that had not responded to other treatment.
Triindevetdeset bolnikov je imelo bolezen v napredovalnem stadiju, ki se ni odzvala na druga zdravljenja.
Ninety-two subjects were randomised by three age cohort strata (2:1) to eltrombopag (n=63) or placebo (n=29).
Dvaindevetdeset bolnikov so v treh starostnih skupinah randomizirali (v razmerju 2:1) na jemanje eltrombopaga (n = 63) ali na jemanje placeba (n = 29).
Nintedanib and its metabolites, the free acid moiety BIBF 1202 and its glucuronide BIBF 1202 glucuronide, did not inhibit or induce CYP enzymes in preclinical studies (see section 5.2).
V predkliničnih študijah nintedanib in njegovi presnovki, prosta kislina BIBF 1202 in njen glukuronid BIBF 1202 niso zavirali ali inducirali encimov CYP (glejte poglavje 5.2).
Nintedanib had no effect on the PK of pirfenidone (see section 4.4).
Nintedanib ni vplival na farmakokinetiko pirfenidona (glejte poglavje 4.4).
Nintedanib inhibits proliferation, migration and fibroblast to myofibroblast transformation of human lung fibroblasts from patients with IPF.
Nintedanib zavira proliferacijo, migracijo in transformacijo humanihpljučnih fibroblastov v miofibroblaste v pljučih bolnikov z IPF.
Nintedanib inhibits the activation of FGFR and PDGFR signalling cascades which are critically involved in proliferation, migration and differentiation of lung fibroblasts/myofibroblasts, the hallmark cells in the pathology of idiopathic pulmonary fibrosis.
Nintedanib zavira aktivacijo signalnih kaskad za FGFR in PDGFR, ki so bistvene za proliferacijo, migracijo in diferenciacijo pljučnih fibroblastov/miofibroblastov, celic, ki so odločilnega pomena v patologiji idiopatske pljučne fibroze.
Nintedanib is a triple angiokinase inhibitor blocking vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and ß) and fibroblast growth factor receptors (FGFR 1-3) kinase activity.
Nintedanib je trojni zaviralec angiokinaze, ki zavira aktivnost kinaze receptorjev žilnega endotelijskega rastnega faktorja (vascular endothelial growth factor receptors – VEGFR 1-3), receptorje rastnega faktorja iz trombocitov (platelet-derived growth factor receptors – PDGFR α in ß) in receptorjev rastnega faktorja fibroblastov (fibroblast growth factor receptors – FGFR 1-3).
Nipple disorder
motnje prsnih bradavic
nipple pain
boleče prsne bradavice
Nipple pain
bolečina v prsnih bradavicah
NIS-LL change from BL
Sprememba pri NIS-LL glede na izhodišče
NIS-LL Responders (% Patients) Difference (Vyndaqel minus Placebo) 95% CI of Difference (p-value)
NIS-LL odzivni bolniki (% bolnikov) Razlika (Vyndaqel minus placebo) 95 % IZ pri razliki (vrednost p)
Nitisinone treatment
Zdravljenje z nitizinonom
nitrates (for chest pain)
nitrate (za bolečino v prsih)
Nitric oxide (NO) 400 ppm mol/mol.
dušikov oksid (NO) 400 ppm mol/mol
Nitric oxide (NO) 400 ppm mol/mol.
Dušikov oksid (NO) 400 ppm mol/mol.
Nitric oxide (NO) 800 ppm mol/mol.
dušikov oksid (NO) 800 ppm mol/mol
Nitric oxide (NO) 800 ppm mol/mol.
Dušikov oksid (NO) 800 ppm mol/mol.
Nitric oxide is genotoxic in some test systems..
Dušikov oksid je genotoksičen v nekaterih testnih sistemih.
Nitrile gloves should be worn when handling patches and cleansing treatment areas.
Med rokovanjem z obliži in čiščenjem zdravljenih predelov nosite nitrilne rokavice.
nitroglycerin and other nitrates, or other substances called “vasodilators”;
nitroglicerina in drugih nitratov ter učinkovin, ki jih imenujemo “vazodilatatorji”;
nitroglycerin and other nitrates, or other substances called “vasodilators”; medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
nitroglicerin in druge nitrate ter učinkovine, ki jih imenujemo “vazodilatatorji”; zdravila za okužbo s HIV ali AIDS (npr. ritonavir, indinavir, nelfinavir);
nitroglycerin and other nitrates, or other substances called “vasodilators”; medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
nitroglicerin in druge nitrate ter učinkovine, ki jih imenujemo “vazodilatatorji”; zdravila za zdravljenje okužb z virusom HIV ali AIDS (npr. ritonavir, indinavir, nelfinavir);
nitroglycerine, a medicine used to treat angina. some types of antibiotics (rifamycin group), ciclosporin (used to prevent rejection of transplanted organs) or antivirals such as ritonavir (used to treat HIV/AIDS). metformin, a medicine used to treat diabetes.
nitroglicerina, zdravila, ki ga uporabljamo pri zdravljenju angine pektoris. nekaterih vrst antibiotikov (iz skupine rifamicinskih antibiotikov), ciklosporina (ki ga uporabljamo za preprečevanje zavrnitve presajenih organov) ali protivirusnih zdravil, kot je ritonavir (ki ga uporabljamo za zdravljenje okužbe z virusom HIV oziroma bolezni AIDS). metformina, zdravila za zdravljenje sladkorne bolezni.
Nitroimidazoles, including metronidazole and misonidazole
Nitroimidazoli, vključno z metronidazolom in mizonidazolom
nITT
nZNZ
Nivestim 12 MU/ 0.2 ml solution for injection/ infusion: each pre-filled syringe contains 12 million units (MU), 120 micrograms of filgrastim in 0.2 ml (corresponding to 0.6 mg/ml).
Nivestim 12 M e./0,2 ml raztopina za injiciranje/infundiranje: ena napolnjena brizga vsebuje 12 milijonov enot (M e.) oziroma 120 mikrogramov filgrastima v 0,2 ml raztopine (kar ustreza koncentraciji 0,6 mg/ml).
Nivestim 12 MU/ 0.2 ml solution for injection/infusion
Nivestim 12 M e./0,2 ml raztopina za injiciranje/infundiranje
Nivestim 12 MU/ 0.2 ml solution for injection/infusion Nivestim 30 MU/ 0.5 ml solution for injection/infusion Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 12 M e./0,2 ml raztopina za injiciranje/infundiranje Nivestim 30 M e./0,5 ml raztopina za injiciranje/infundiranje Nivestim 48 M e./0,5 ml raztopina za injiciranje/infundiranje
Nivestim 12 MU/ 0.2 ml solution for injection/infusion,
Nivestim 12 M e./0,2 ml raztopina za injiciranje/infundiranje
Nivestim 12 MU/0.2 ml solution for injection/infusion Filgrastim
Nivestim 12 M e./0,2 ml raztopina za injiciranje/infundiranje filgrastim
Nivestim 12 MU/0.2 ml solution for injection/infusion Nivestim 30 MU/0.5 ml solution for injection/infusion Nivestim 48 MU/0.5 ml solution for injection/infusion Filgrastim
Nivestim 12 M e./0,2 ml raztopina za injiciranje/infundiranje Nivestim 30 M e./0,5 ml raztopina za injiciranje/infundiranje Nivestim 48 M e./0,5 ml raztopina za injiciranje/infundiranje filgrastim
Nivestim 30 MU 0.5 ml solution for injection/infusion Filgrastim
Nivestim 30 M e./0,5 ml raztopina za injiciranje/infundiranje filgrastim
Nivestim 30 MU/ 0.5 ml solution for injection/ infusion: each pre-filled syringe contains 30 million units (MU), 300 micrograms of filgrastim in 0.5 ml (corresponding to 0.6 mg/ml).
Nivestim 30 M e./0,5 ml raztopina za injiciranje/infundiranje: ena napolnjena brizga vsebuje 30 milijonov enot (M e.) oziroma 300 mikrogramov filgrastima v 0,5 ml raztopine (kar ustreza koncentraciji 0,6 mg/ml).
Nivestim 30 MU/ 0.5 ml solution for injection/infusion
Nivestim 30 M e./0,5 ml raztopina za injiciranje/infundiranje
Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 30 M e./0,5 ml raztopina za injiciranje/infundiranje, Nivestim 48 M e./0,5 ml raztopina za injiciranje/infundiranje
Nivestim 48 MU/ 0.5 ml solution for injection/ infusion: each pre-filled syringe contains 48 million units (MU), 480 micrograms of filgrastim in 0.5 ml (corresponding to 0.96 mg/ml).
Nivestim 48 M e./0,5 ml raztopina za injiciranje/infundiranje: ena napolnjena brizga vsebuje 48 milijonov enot (M e.) oziroma 480 mikrogramov filgrastima v 0,5 ml raztopine (kar ustreza koncentraciji 0,96 mg/ml).
Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 48 M e./0,5 ml raztopina za injiciranje/infundiranje
Nivestim 48 MU/0.5 ml solution for injection/infusion Filgrastim
Nivestim 48 M e./0,5 ml raztopina za injiciranje/infundiranje filgrastim
Nivestim can be used:
Zdravilo Nivestim lahko uporabljamo:
Nivestim containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes.
Zdravilo Nivestim vsebuje r-metHuG-CSF (filgrastim), ki povzroča izrazito povečanje števila nevtrofilcev v periferni krvi v roku 24 ur, z manjšim povečanjem števila monocitov.
Nivestim contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially sodium-free.
Zdravilo Nivestim vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni »brez natrija«.
Nivestim contains no preservative.
Zdravilo Nivestim ne vsebuje konzervansov.
Nivestim contains sodium and sorbitol
Zdravilo Nivestim vsebuje natrij in sorbitol
Nivestim is a clear colourless solution for injection/ infusion in a glass pre-filled syringe with an injection needle (stainless steel) with a needle guard.
Zdravilo Nivestim je bistra in brezbarvna raztopina za injiciranje/infundiranje v steklenih napolnjenih brizgah z injekcijsko iglo (iz nerjavečega jekla) in z varnostno zaščito.
Nivestim is a solution for injection or infusion (drip into a vein) that contains the active substance filgrastim.
Zdravilo Nivestim je raztopina za injiciranje ali infundiranje (kapalna infuzija v veno), ki vsebuje zdravilno učinkovino filgrastim.
Nivestim is a white blood cell growth factor (granulocyte colony stimulating factor) and belong to a group of medicines called cytokines.
Zdravilo Nivestim je rastni faktor za bele krvničke (granulocitne kolonije stimulirajoči faktor) in spada v skupino zdravil, imenovanih citokini.
Nivestim is a ‘biosimilar’ medicine.
Zdravilo Nivestim je „biološko podobno“ zdravilo.
Nivestim is given by injection under the skin or infusion into a vein.
Zdravilo Nivestim se injicira pod kožo ali infundira v veno.
Nivestim is used to stimulate the production of white blood cells in the following situations:
Zdravilo Nivestim se uporablja za stimulacijo tvorbe belih krvnih celic v naslednjih primerih:
Nivestim is usually given as a daily injection into the tissue under the skin (known as a subcutaneous injection).
Zdravilo Nivestim običajno dajemo vsakodnevno v obliki injekcije v tkivo tik pod kožo (temu pravimo subkutana injekcija).
Nivestim is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately.
Zdravilo Nivestim se običajno daje v specializiranih centrih za zdravljenje, čeprav si lahko bolniki, ki prejemajo podkožno injekcijo in so bili ustrezno usposobljeni, cepivo vbrizgajo sami.
Nivestim must not be diluted with sodium chloride solution.
Zdravila Nivestim ne smete redčiti z raztopinami natrijevega klorida.
Nivestim must not be diluted with sodium chloride solutions.
Zdravila Nivestim se ne sme redčiti z raztopinami natrijevega klorida.
Nivestim should not affect your ability to drive and use machines.
Zdravilo Nivestim ne bi smelo vplivati na sposobnost upravljanja vozil in strojev.
Nivestim should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.
Zdravilo Nivestim se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) filgrastim ali katero koli drugo sestavino zdravila.
Nivestim was compared with Neupogen in one main study involving 279 women with breast cancer who were being treated with anticancer medicines.
Zdravilo Nivestim so primerjali z zdravilom Neupogen v eni glavni študiji z 279 ženskami z rakom dojke, ki so jih zdravili z zdravili proti raku.
Nivestim was studied to show that it is comparable to the reference medicine, Neupogen.
Zdravilo Nivestim so proučevali, da bi dokazali, da je primerljivo z referenčnim zdravilom Neupogen.
Nivolumab + Ipilimumab
Število ogroženih oseb nivolumab + ipilimumab
Nivolumab 3 mg/kg (events : 86/135), median and 95% CI : 9.23 (7.33, 13.27)
Nivolumab 3 mg/kg (dogodki: 86/135), mediana in 95 % IZ: 9,23 (7,33; 13,27)
Nivolumab 3 mg/kg showed an overall response rate of 14.5% (95% CI: 8.7,22.2%), a median OS of 8.21 months (95% CI: 6.05,10.9), and a median PFS of 1.87 months (95% CI 1.77,3.15).
Pri uporabi nivolumaba v odmerku 3 mg/kg je delež celokupnega odziva znašal 14,5 % (95 % interval zaupanja: 8,7; 22,2 %), mediana celokupnega preživetja 8,21 meseca (95 % interval zaupanja: 6,05; 10,9 meseca), mediana preživetja brez napredovanja bolezni pa 1,87 meseca (95 % interval zaupanja: 1,77; 3,15 meseca).
Nivolumab attaches to a target protein called programmed death-1 receptor (PD-1) that can switch off the activity of T cells (a type of white blood cell that forms part of the immune system, the body’s natural defences).
Nivolumab se pritrdi na ciljno beljakovino, imenovano receptor za programirano celično smrt-1 (PD-1), ki lahko zavre aktivnost celic T (vrsta belih krvnih celic, ki so sestavni del imunskega sistema, naravne obrambe telesa).
Nivolumab BMS 10 mg/mL concentrate for solution for infusion nivolumab
Nivolumab BMS 10 mg/ml koncentrat za raztopino za infundiranje nivolumab
Nivolumab BMS 10 mg/mL concentrate for solution for infusion.
Nivolumab BMS 10 mg/ml koncentrat za raztopino za infundiranje
Nivolumab BMS 10 mg/mL sterile concentrate nivolumab
Nivolumab BMS 10 mg/ml sterilni koncentrat
Nivolumab BMS can be used for intravenous administration either:
Zdravilo Nivolumab BMS se lahko aplicira intravensko:
Nivolumab BMS can only be obtained with a prescription and treatment must be started and supervised by a doctor experienced in the treatment of cancer.
Izdaja zdravila Nivolumab BMS je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem raka.
Nivolumab BMS concentrate for solution for infusion (sterile concentrate) is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles.
Nivolumab BMS koncentrat za raztopino za infundiranje (sterilni koncentrat) je bistra do opalescentna, brezbarvna do svetlorumena tekočina, ki lahko vsebuje manjše število neznatnih delcev.
Nivolumab BMS concentrate is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles.
Koncentrat zdravila Nivolumab BMS je bistra do opalescentna, brezbarvna do svetlorumena tekočina, ki lahko vsebuje manjše število neznatnih delcev.
Nivolumab BMS have been shown to improve patients’ survival in one main study involving 272 patients with previously treated squamous NSCLC that was advanced or had spread throughout the body.
V eni glavni študiji, ki je vključevala 272 bolnikov s predhodno zdravljenim ploščatoceličnim nedrobnoceličnim pljučnim karcinomom, ki je napredoval ali se razširil po telesu, so dokazali, da je zdravilo Nivolumab BMS izboljšalo preživetje bolnikov.
Nivolumab BMS infusion
Raztopina zdravila Nivolumab BMS, pripravljena za infundiranje
Nivolumab BMS infusion is compatible with PVC and polyolefin containers, glass bottles, PVC infusion sets and in-line filters with polyethersulfone membranes with pore sizes of 0.2 µm to 1.2 µm.
Nivolumab BMS raztopina za infundiranje je kompatibilna z vsebniki iz PVC-ja in poliolefina, steklenicami, infuzijskimi sistemi iz PVC-ja in linijskimi filtri z membranami iz polietersulfona z velikostjo por od 0,2 µm do 1,2 µm.
Nivolumab BMS infusion must be completed within 24 hours of preparation.
Infundiranje zdravila Nivolumab BMS je treba dokončati v 24 urah po pripravi.
Nivolumab BMS is a medicine used to treat advanced non-small cell lung cancer (a type of lung cancer) in adults.
Zdravilo Nivolumab BMS uporabljamo za zdravljenje napredovalega nedrobnoceličnega pljučnega raka (vrsta pljučnega raka) pri odraslih.
Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Zdravilo Nivolumab BMS je indicirano za zdravljenje lokalno napredovalega ali metastatskega ploščatoceličnega nedrobnoceličnega pljučnega raka (NSCLC - non-small cell lung cancer) po predhodni kemoterapiji pri odraslih.
Nivolumab BMS must be administered with caution in patients with moderate (total bilirubin > 1.5 × to 3 × the upper limit of normal [ULN] and any AST) or severe (total bilirubin > 3 × ULN and any AST) hepatic impairment.
Pri bolnikih z zmerno (vrednost skupnega bilirubina > 1,5 × do 3 × zgornja meja normalne vrednosti [ZMN] in katera koli
Nivolumab BMS should not be used in children and adolescents below 18 years of age.
Zdravila Nivolumab BMS se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Nivolumab has been designed to attach to a receptor called PD-1 which is found on certain cells of the immune system called T cells.
Učinkovina nivolumab je bila zasnovana tako, da se veže na receptor, imenovan PD-1, ki je v nekaterih celicah imunskega sistema, imenovanih celice T. Rakave celice lahko tvorijo beljakovine (PD-1 in